We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GD:NYSEGeneral Dynamics Corporation Analysis

Data as of 2026-05-25 - not real-time

$342.89

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

General Dynamics (GD) trades near its 20‑day SMA, with the 20‑day and 50‑day SMAs essentially flat, signaling a neutral price trend. The MACD histogram remains positive and the RSI sits around the 50‑point mid‑range, suggesting limited downside pressure while the market sentiment index is in "Extreme Greed" territory. Fundamentally, the stock appears undervalued – its forward P/E of ~19 is well below the industry average of ~30, and the DCF‑derived fair value of roughly $370 implies about a 14% upside from the current $342 price. Revenue growth of just over 10% YoY, a robust order backlog exceeding $26 billion, and a sustainable dividend yield of 1.78% with a 38% payout further bolster the case.
Defense spending is accelerating, providing a tailwind for GD’s four business segments, while the company’s low beta (~0.5) and solid cash generation reduce market‑risk exposure. However, decreasing volume and a 30‑day volatility near 29% signal heightened short‑term price swings. Overall, the blend of attractive valuation, growth prospects, and defensive sector dynamics makes GD a compelling buy for medium‑ to long‑term horizons, with a cautious hold stance in the immediate term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Neutral technical trend with price hugging the 20‑day SMA
  • Positive MACD but decreasing volume indicating possible consolidation
  • Elevated short‑term volatility (~29% 30‑day)

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued relative to peers (PE ~21 vs industry ~30)
  • DCF upside of ~14% and strong order backlog
  • Sustained revenue growth and solid cash flow generation

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Long‑term defense spending surge supporting all segments
  • Stable dividend yield with low payout ratio
  • Low beta and strong balance sheet reducing systemic risk

Key Metrics & Analysis

Financial Health

Revenue Growth10.30%
Profit Margin8.07%
P/E Ratio21.6
ROE17.97%
ROA6.00%
Debt/Equity37.70
P/B Ratio3.6
Op. Cash Flow$7.4B
Free Cash Flow$5.3B
Industry P/E29.7

Technical Analysis

TrendNeutral
RSI52.6
Support$306.77
Resistance$353.57
MA 20$340.32
MA 50$341.58
MA 200$341.21
MACDBullish
VolumeDecreasing
Fear & Greed Index91.66

Valuation

Fair Value$370.07
Target Price$391.55
Upside/Downside14.19%
GradeUndervalued
TypeBlend
Dividend Yield1.78%

Risk Assessment

Beta0.53
Volatility28.62%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.